The biotech ETF outpaced the Nasdaq Biotechnology Index’s 8.5% November gain as investors rotated into smaller companies with drugs in late-stage development. SBIO attracted $19.54 million in net inflows during the past month. That brought total assets to $116.8 million, according to ETF Database.
SBIO focuses on biotech companies that have at least one drug in Phase II or III clinical trials, according to the research. This strategy zeroes in on firms with near-term catalysts while avoiding very early-stage companies. As Federal Reserve rate cuts improve financing conditions and merger activity picks up, the fund offers investors a way to tap into companies where trial results and acquisition bids can drive sharp stock moves.
November’s rally was driven by several high-profile movers within SBIO’s lineup. Terns Pharmaceuticals, Inc. (TERN) jumped 240.3% after releasing Phase I data for its chronic myeloid leukemia candidate that showed deep reductions in disease burden with a clean safety profile, according to the SS&C report.
Olema Pharmaceuticals, Inc. (OLMA) gained 215.7% in November after Roche reported successful Phase III results for its oral breast cancer treatment. That’s prompted investors to reassess opportunities for Olema’s own late-stage oral drug, according to the research.
Biotech ETF Benefits From Policy Shift
Federal Reserve rate cuts have improved the backdrop for biotech investments by lowering borrowing costs and supporting long-duration growth stories like drug pipelines, according to SS&C. The Nasdaq Biotechnology Index has responded with mid-single digit gains over the past month and high-teens returns over three months.
SBIO has broken out to new 52-week highs as funding conditions improve. Over the past six months, the fund returned about 71.8%, beating the S&P Biotechnology Select Industry Index by more than 16 percentage points and outpacing the S&P 500 Index by over 55 percentage points, according to the SS&C research.
Biopharma mergers and acquisitions in 2025 have already surpassed last year’s totals, according to the report. Large pharmaceutical companies are looking to backfill pipelines ahead of a patent expiry wave.
VettaFi LLC (“VettaFi”) is the index provider for SBIO, for which it receives an index licensing fee. However, SBIO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of SBIO.
For more news, information, and analysis, visit the ETF Building Blocks Content Hub.
